InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro Quality Score

53.1/100

Rank #1,407 of 2,960 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

INMD Stock Analysis & AI Quality Score

Data updated 2026-09-12

AI stock analysis and institutional research for InMode Ltd. (INMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores INMD at 53.1/100 on a 32-signal composite quality model, placing it at rank #1,407 of 2,960 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), InMode Ltd. reports quarterly revenue of $370.5M, net income of $93.8M, an operating margin of 23.1%. Top institutional holders of INMD by reported 13-F value include Doma Perpetual Capital Management, ACADIAN ASSET MANAGEMENT, BlackRock, based on the most recent SEC filings. INMD trades on the Nasdaq exchange and files with the SEC under CIK 1742692. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for InMode Ltd. directly from SEC EDGAR. InMode Ltd.'s 13F Pro composite quality score has ranged between 52 and 54 since 2026, currently 53.1 — a stable long-term trajectory across 48 quarterly and live scoring snapshots.

Revenue

FY 2025

$370.5M

Net Income

FY 2025

$93.8M

Free Cash Flow

FY 2025

$84.3M

Operating Margin

FY 2025

23.1%

ROIC

FY 2025

12.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-6.2% YoY
$370.5MFY 2025
FY22 $454.3MFY23 $492.0MFY24 $394.8MFY25 $370.5M

Net Income

FY 2025
FY22 $161.5MFY23 $197.9MFY24 FY25

Operating Income

-24.1% YoY
$85.4MFY 2025
FY22 $197.9MFY23 $195.7MFY24 $112.5MFY25 $85.4M

EPS (Diluted)

-36.4% YoY
$1.43FY 2025
FY22 $1.89FY23 $2.30FY24 $2.25FY25 $1.43

Total Assets

-2.4% YoY
$766.4MFY 2025
FY22 $644.4MFY23 $863.3MFY24 $785.7MFY25 $766.4M

Op. Cash Flow

-35.7% YoY
$85.3MFY 2025
FY22 $181.6MFY23 $176.8MFY24 $132.7MFY25 $85.3M

Free Cash Flow

-36.1% YoY
$84.3MFY 2025
FY22 $180.0MFY23 $176.1MFY24 $132.0MFY25 $84.3M

Get alerted when INMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for InMode Ltd. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Top Institutional Holders of INMD

Companies Similar to INMD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

PBYI

PUMA BIOTECHNOLOGY, INC.

48
AI score
Similar quality profile · 7 shared holders
EMBC

Embecta Corp.

50
AI score
Similar quality profile · 8 shared holders
CGEN

COMPUGEN LTD

52
AI score
Similar quality profile · 3 shared holders
AMPH

Amphastar Pharmaceuticals, Inc.

48
AI score
Similar quality profile · 5 shared holders
LNTH

Lantheus Holdings, Inc.

58
AI score
Similar quality profile · 4 shared holders
PCRX

Pacira BioSciences, Inc.

52
AI score
Similar quality profile · 6 shared holders
UTMD

UTAH MEDICAL PRODUCTS INC

47
AI score
Similar quality profile · 4 shared holders
TECH

BIO-TECHNE Corp

58
AI score
Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

Put INMD on your watchlist

Track score changes the day InMode Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is INMD a good stock to buy?

13F Pro's AI-powered analysis of InMode Ltd. (INMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INMD are available on the INMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INMD is classified as a small company.

Which hedge funds own INMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of InMode Ltd.'s investment landscape.